文献速递心脏核医学

缺血性心肌病患者心肌葡萄糖利用定量评估的临床意义

Clinical significance of quantitative assessment of glucose utilization in patients with ischemic cardiomyopathy.
PubMed 文献 · J Nucl Cardiol · 2018-08-14

本研究前瞻性纳入79例缺血性心肌病患者,行动态心脏FDG PET定量心肌葡萄糖摄取率(MRGlu),并随访至少6个月。结果显示存活心肌MRGlu显著高于非存活心肌,透壁匹配区MRGlu≥23.40或反向匹配区MRGlu≥36.90者预后更差。

要点

  • 存活心肌的MRGlu显著高于非存活心肌。
  • 透壁匹配区MRGlu≥23.40或反向匹配区MRGlu≥36.90者预后更差。
  • 他汀类和DPP4i等药物影响心肌葡萄糖利用。

核心结论

  • 心肌葡萄糖利用受底物和药物(包括他汀类和DPP4i)影响。
  • MRGlu可区分存活与非存活心肌。
  • 透壁匹配区和反向匹配区的MRGlu可能是缺血性心肌病患者心血管死亡的预后预测因子。

研究设计与样本

  • 前瞻性纳入79例缺血性心肌病患者,行动态心脏FDG PET,随访至少6个月。
  • 基于201Tl SPECT和FDG PET的视觉评分分析确定灌注-代谢模式。
  • 采用Patlak动力学模型分析MRGlu。
  • 主要终点为心血管死亡。

主要发现

  • 存活心肌的MRGlu显著高于非存活心肌。
  • 透壁匹配区MRGlu与高脂血症病史、他汀类使用和甘油三酯水平呈负相关。
  • 接受DPP4i治疗的糖尿病患者在透壁匹配、不匹配和反向匹配区的MRGlu显著更低。
  • 透壁匹配区MRGlu≥23.40或反向匹配区MRGlu≥36.90的患者预后更差。

关键数值与推荐

  • 透壁匹配区MRGlu≥23.40与更差预后相关。
  • 反向匹配区MRGlu≥36.90与更差预后相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The aim of this study was to prospectively quantify the rate of myocardial glucose uptake (MRGlu) in myocardium with different perfusion-metabolism patterns and determine its prognostic value in patients with ischemic cardiomyopathy. METHODS AND RESULTS: 79 patients with ischemic cardiomyopathy were prospectively enrolled for dynamic cardiac FDG PET, and then followed for at least 6 months. Perfusion-metabolism patterns were determined based on visual score analysis of 201Tl SPECT and FDG PET. MRGlu was analyzed using the Patlak kinetic model. The primary end-point was cardiovascular mortality. Significantly higher MRGlu was observed in viable compared with non-viable areas. Negative correlations were found between MRGlu in transmural match and a history of hyperlipidemia, statin usage, and triglyceride levels. Diabetic patients receiving dipeptidyl peptidase-4 inhibitors (DPP4i) had a significantly lower MRGlu in transmural match, mismatch, and reverse mismatch. Patients with MRGlu in transmural match ≥ 23.40 or reverse mismatch ≥ 36.90 had a worse outcome. CONCLUSIONS: Myocardial glucose utilization was influenced by substrates and medications, including statins and DPP4i. MRGlu could discriminate between viable and non-viable myocardium, and MRGlu in transmural match and reverse mismatch may be prognostic predictors of cardiovascular death in patients with ischemic cardiomyopathy.

来源:J Nucl Cardiol,查看原文。版权归原作者所有。

引用

  1. Ko KY, Wang SY, Yen RF, et al. Clinical significance of quantitative assessment of glucose utilization in patients with ischemic cardiomyopathy. J Nucl Cardiol. 2018. PMID: 30109593. doi:10.1007/s12350-018-1395-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。